Seno names Keane as CMO

TriMed Staff | | Health Imaging | Artificial Intelligence
Seno Medical Instruments, a developer of opto-acoustic cancer platform technology, has appointed William F. Keane, MD, as its chief medical officer (CMO).

In this capacity, Keane will focus on the clinical utilization of opto-acoustic imaging technology, moving the technology through clinical studies for use in the diagnosis and treatment of cancer, according to the San Antonio-based Seno.

Previously, the company said that he was CMO at Reliant Pharmaceuticals, which was acquired by GlaxoSmithKline, where he provided for the integration of the two organizations’ scientific and medical endeavors. He has served as vice president of U.S. medical and scientific affairs at Merck, and served as chairman of the department of medicine at Hennepin County Medical Center in Minneapolis, and vice-chairman of the department of medicine at the University of Minnesota in Minneapolis.

TriMed Staff

Related Content

AI beats standard regression models at predicting lung cancer risk
AI reduces CT lung cancer screening workload by nearly 80%
How AI and CCTA help heart teams plan ahead before PCI
5 steps for evaluating radiology AI applications
Adaptable AI system detects subtle changes in imaging, has potential across multiple clinical settings
New algorithm models radiologists' eye movements to interpret chest X-rays

Around the web

Cardiovascular Business
ASE updates recommendations for assessing right heart function in patients with pulmonary hypertension

The new guidelines were designed to ensure sonographers and other members of the heart team have the information they need to screen patients when appropriate and identify early warnings signs of PH. 

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
‘A significant milestone’: First US patients receive doses of new PET radiotracer for CAD

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care.